Introduction
The development of hematopoietic cells is a complex process involving multiple levels of control 1 allowing immature stem cells and progenitor cells to differentiate into functionally mature blood cells. The process of hematopoietic stem cell differentiation is a tightly regulated process with cell surface receptor-ligand interactions transmitting external signals to second messengers in the cytoplasm which transmit signals to nuclear transcription factors regulating gene expression. Transcription factors interact with promoter/enhancer elements of genes to enhance or repress transcription by RNA polymerase. Several classes of transcription factors have been characterized based on their ability to bind to promoter elements and alter gene expression. 2 Different classes of transcription factors have been defined based on their DNA binding motifs. 3 Some of these transcription factor classes include the helix-turn-helix motif (eg homeobox genes), 4 leucine zipperbasic DNA binding domain (c-myc, fos/jun), 5 and the zinc finger motif (steroid-thyroid hormone receptors). 6 The zinc finger motif consists of 12 amino acids that form a loop anchored at the base by histidine and cysteine residues that coordinate a zinc atom. One type of zinc finger, C2H2, contains the highly conserved peptide motif CX2CX3FX5LX2HX3H, exemplified by the transcription factor, Sp1. 7 Most transcription factors contain multiple zinc fingers separated by conserved regions, TGEKPYX, termed the H-C link. Many of the C2H2 zinc finger family members regulate growth and differentiation with specific mutations resulting in human disease. [8] [9] [10] The myeloid zinc finger gene, MZF-1, is a C2H2 transcription factor originally cloned from a cDNA library from a patient with chronic myelogenous leukemia. 11 Analysis of isolated MZF-1 genomic clones indicates that MZF-1 is a single copy gene about 3 kb in size without introns. 12 Several lines of evidence suggest that MZF-1 is involved in early myelopoiesis. MZF-1 is specifically expressed in myeloid leukemia cells and myeloid progenitor cells at the myelocyte and metamyelocyte stage from normal marrow and not in later stages, or cells of other lineages (lymphocytes, erythroid, megakaryocytes). 11, 13 The specificity for granulocyte differentiation is also supported by the fact that basal MZF-1 expression increases in myeloid HL-60 cells induced to differentiate along the granulocyte pathway with retinoic acid or DMSO but not if they are induced down the monocyte/macrophage lineage with TPA. 11 Moreover, antisense MZF-1 inhibits granulocyte colony formation from normal human marrow in vitro. 13 There are 13 zinc fingers in the MZF-1 gene arranged in two domains (zinc fingers 1-4 and 5-13) with both domains binding similar DNA sequences. 14 One piece of evidence that MZF can act as a hematopoietic transcription factor stems from experiments with CD34. MZF-1 consensus DNA binding sites have been identified in the CD34 promoter and MZF-1 was found to regulate the CD34 promoter in vitro. 15 Two lines of evidence suggest that MZF-1 functions to control cell proliferation: (1) When MZF-1 is overexpressed in the murine myeloid cell line FDCP.1, the programmed cell death these cells normally undergo in the absence of IL-3 is inhibited. 16 Moreover, when FDCP.1 cells overexpressing MZF-1 are injected into nude mice, tumors develop at the site of injection that express the MZF-1 transgene. (2) Retroviral transduction of NIH 3T3 cells with MZF-1 also results in a 'transformed' phenotype with the cells forming piled up foci. 17 These studies suggest that dysregulated expression of MZF-1 could contribute to oncogenesis.
The human myeloid leukemia cell line, HL-60, has been a useful model to study myelopoiesis as these cells respond to retinoic acid with terminal granulocytic differentiation. As a logical extension of these previous studies in murine cells and to characterize further the role of MZF-1 in human myelopo- iesis, we have overexpressed MZF-1 in the human myeloid leukemia cell line, HL-60, using retroviral gene transduction. In this report we show that MZF-1 delays RA-induced differentiation and apoptosis in HL-60 cells. In light of these findings, we discuss a possible physiologic role for MZF-1 during myelopoiesis.
Materials and methods

Cell lines
The HL-60 myeloid leukemia cell line 18 and HL-60 retrovirally transduced clones were maintained in liquid suspension culture in RPMI 1640 plus 5% heat inactivated fetal calf serum with antibiotics. PE501 ecotropic and PA317 amphotropic packaging cell lines and NIH 3T3 thymidine kinase negative cells 19 were maintained as adherent cultures in Dulbecco's modified Eagle's medium (DMEM) plus 10% heat inactivated fetal calf serum with antibiotics. All-trans-retinoic acid (Sigma Chemical, St Louis, MO, USA) was added to cultures from a stock solution of 4 mmol/l in ethanol made fresh daily and kept in the dark at −20°C until use. PMA (phorbol 12-myristate 13-acetate) (Sigma) was solubilized in DMSO to give a 1 mM stock solution kept at −20°C. PMA was added to cultures to give a concentration of 0.5-10 nM with the concentration of DMSO less than 0.01%. Morphologic evaluation of cells was performed by sedimenting cells (5 × 10 4 ) on to glass slides with a Shandon Cytospin 3 cytocentrifuge (Pittsburgh, PA, USA), followed by Wright's staining. Cells were enumerated using a hemocytometer after trypan blue staining.
Retroviral vector construction and production The 1.8 kB cDNA of MZF-1 open reading frame was cloned into the EcoRI site of the retroviral vector LXSN to produce LMZFSN. This vector expresses the MZF-I cDNA insert driven by the Moloney murine leukemia virus long terminal repeat (LTR), and expression of the selectable marker neomycin phosphotransferase (Neo) is driven by the simian virus 40 (SV 40) promoter. 19 Virus was generated from the recombinant retroviral vector plasmid (designated LMZFSN; see Figure 1 ) as pre- viously described. 17, 20 Briefly, 20 g of plasmid were transfected using CaPO 4 into the PE501 ecotropic packing cell line and selected in G418 from which supernatants were used to transduce the amphotrophic packaging cell line PA317. Infected PA317 clones were isolated and expanded in G418 (1 mg/ml). Titers of producers expressing MZF-1 were determined on NIH 3T3 thymidine kinase-negative target cells as previously described. 20 One clone had a titer of 1. standard procedures. 21 Blots were hybridized to labeled probes according to standard procedures, 22 except that ExpressHyb solution (Clontech Laboratories, Palo Alto, CA, USA) was used as a prehybridization and hybridization solution with a hybridization time of 4 h. The final wash was carried out at 60°C.
Molecular probes
The molecular probes used in Northern blot hybridization included RAR-␣, the 2.8 kb length cDNA, 20 MZF-1,1.0 kb R10 fragment, 11 CD18, a 1.8 kb EcoRI fragment, 23 c-myc, 2.5 kb Xho fragment (a gift from DA Williams, Indiana University Medical Center, Indianapolis, IN, USA), HuBA-1, human ␤-actin 1.3 kb RI fragment cloned from a human HL-60 cDNA library (a gift from R Zirngibl and J Rossant, Mt. Sinai Hospital Res. Inst., Toronto, Canada). These probes were labeled by 32 P random oligonucleotide priming. Radiolabeled probe for human bcl-2 was generated using asymmetric PCR 24 and bcl-2 primers previously described. 25 
Western blotting
Western blots were performed using whole cell extracts electrophoresed on 12% SDS-PAGE and electroblotted on to 0.2 micron nitrocellulose. 26 Protein levels in the extracts were quantitated using Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA, USA) and equal amounts (20 g) of protein were loaded per lane. The gels were transferred for 1 h on to nitrocellulose and stained with Poinceu Red to confirm equal loading between lanes. The filter was incubated in blocking buffer which contains 5% non-fat milk for 1 h. Mouse monoclonal anti-human bcl-2 (Zymed Laboratories, San Francisco, CA, USA) diluted to the appropriate concentration was incubated with the filter overnight at 4°C. The filter was washed in TBST and incubated in TBST containing 5% milk and CD-18 expression in HL-60 and HL-60-MZF-1 cells. Cells were treated for 6 days with 10 M retinoic acid, harvested and then incubated with anti-CD18 monoclonal antibody conjugated with FITC. Cells were examined by flow microfluorimetry using a FAC-SCAN system (Beckton Dickinson), and cell labeling was expressed as relative fluorescence intensity (488 nm) compared to isotype controls. The x axis represents relative fluorescence and the y axis cell counts.
detected using the Boehringer-Mannheim chemiluminescent system (Boehringer Manheim). The bands were visualized using autoradiographic film.
Apoptosis assays
DNA fragmentation was quantitated in three ways. First, internucleosomal DNA fragmentation was assessed by electrophoresis in an agarose gel. Cells were treated with RA (10 M) or ethanol (0.25%) or camptothecin (0.05 g/ml) (Sigma). A total of 10 6 cells were lysed, digested with proteinase K and ribonuclease, run on a 2% agarose gel, stained with ethidium bromide, and photographed. 27 Second, total fragmented DNA was determined using a diphenylamine assay exactly as previously described. 26 Briefly, cells were lysed in hypotonic Triton ×100 detergent buffer followed by perchloric acid precipitation of the DNA in the pellet and supernatant. DNA in each fraction was then quantitated spectrophotometrically (A 600 ) using the diphenylamine reaction and expressed as % soluble or fractionated DNA. Third, the percent cells undergoing apoptosis was determined using the TdT-mediated dUTP-fluorescein nick end-labeling (TUNEL) reaction following the manufacturer's instructions (Boehringer Manheim). Briefly, cytocentrifuge preparations of cells were fixed in 10% formalin for 30 min, washed in PBS, and incubated with the terminal transferase containing fluorescein-dUTP in a humidified chamber for 60 min. Slides were rinsed three times with PBS, coverslipped, and visualized on a Zeiss Fluorescent microscope. Random fields of cells were photographed using phase contrast and fluorescent microscopy. Slides were projected on a marker board and 100 cells counted randomly from the phase contrast images followed by scoring fluorescent positive cells from the 100 selected phase cells. To Differential gene expression in RA-treated HL-60 and HL-60-MZF-1 cells. RNA was extracted from HL-60 (lanes 1-4) and HL-60-MZF-1 (lanes 5-8) cells following exposure to RA for 0 days (lanes 1 and 5), 2 days (lanes 2 and 6), 4 days (lanes 3 and 7), and 6 days (lanes 4 and 8). Total RNA was subjected to Northern blot hybridization with the indicated probes. These probes are described in Materials and methods. eliminate bias, all counts were done in a blinded fashion so that the individuals counting and scoring cells were unaware as to which samples were being projected.
Flow cytometric analysis
For flow cytometric assays, 2 × 10 5 cells were pelleted at 700 g for 5 min and washed with phosphate-buffered saline containing 2% human albumin (PBS-AB). The cells were resuspended in 100 l PBS-AB with 2 l primary antibody conjugated with FITC, incubated at 4°C for 20 min, and washed twice with PBS-AB. The pellet was resuspended in 1 ml PBS-AB. Cells were examined by flow microfluorimetry using a FACSCAN system (Becton Dickinson), and cell labeling was expressed as relative fluorescence intensity (488 nm) 
Results
Retroviral-mediated transduction of MZF-1 into HL-60 cells
To evaluate further the role of MZF-1 in myeloid differentiation, we used retroviral gene transduction to overexpress MZF-1 in HL-60 cells. We constructed a retroviral vector harboring MZF-1 cDNA (Figure 1 ) and used this vector to introduce MZF-1 into HL-60 cells as previously described. 17, 20 The endogenous MZF-1 transcripts (3, 7.5 and 9 kb) are low abundance transcripts detected in developing myeloid cells including HL-60 cells using poly(A+) RNA. 11 The retroviral MZF-1 transcript (4.7 kb) was expressed at a high level and detected on Northern blot using total RNA (Figure 1) . After exposure to retinoic acid for 3 days, there was an induction of the retroviral MZF-1 transcript, but the endogenous MZF-1 remained undetectable on Northerns using total RNA. We have observed a similar upregulation of retroviral LXSN transcripts after exposure to RA with other inserts. 26, 28 The increased expression is likely secondary to enhanced transcriptional activity of the retroviral LTR previously described in RA-induced HL-60 cells. (Figure 2) . The ethanol-treated controls reach their highest cell number after 8 days with a subsequent decline in number as the cells outgrow their media. 26 The HL-60-MZF-1 cells continue to proliferate in response to RA (Figure 2) , with the peak cell counts occurring somewhat later at 4-6 days of exposure to 10 −5 and 10
RA, respectively. The ethanol treated HL-60-MZF-1 controls also reach peak counts at a later time, after 10 days, and do not begin to exhibit significant cell death until after 12 days in culture (Figure 2 ). Additionally, cell cycle analysis ( Figure 3 ) using propidium iodide and flow cytometry demonstrated that the MZF-1 transduced cells have significantly higher numbers of cells in S-phase after treatment with RA (10 −6 M) compared to parental HL-60 cells (42% vs 28% after 4 days, and 15% vs 6% afer 6 days). Thus, although the parental and MZFtransduced HL-60 cells appear to grow at similar rates DNA fragmentation patterns in HL-60 and HL-60-MZF-1 cells. Internucleosomal DNA fragmentation patterns were determined on HL-60 (lanes 1-3) and HL-60-MZF-1 (lanes 4-6) cells following exposure to camptothecin (0.05 g/ml for 4 h) (lanes 1 and 4), ethanol (0.25% for 6 days) (lanes 2 and 5), or RA (10 M for 6 days) (lanes 3 and 6). One million cells were loaded into each lane, lysed, digested with ribonuclease and proteinase K, and electrophoresed on a 2% agarose gel, followed by staining with ethidium bromide (see Materials and methods). (Figure 2 ), RA-induced growth inhibition is delayed in HL-60 cells overexpressing the MZF-1 gene.
We also assayed the RA-treated cells for morphologic differentiation by performing differential cell counts on Wright stained cytocentrifuged cells. Differential counts were done in blinded fashion so the person doing the counts did not know which sample they were counting until all counts were completed. Both parental HL-60 and the transduced HL-60-MZF-1 cells showed a similar degree of spontaneous differentiation after ethanol treatment and growth in culture for 6 days (Figure 4) . Although only half as many of the HL-60-MZF-1 cells compared to the wild-type HL-60 cells had differentiated after 3 days of RA exposure (Figure 4) , both cell types responded with 80-95% mature granulocytes after treatment with RA for 6 days (Figure 4) . Thus, MZF-1 overexpression can delay RA induced growth inhibition/induce cell proliferation and during that process delay morphologic differentiation in HL-60 cells. We also exposed HL-60 and HL-60-MZF-1 cells to 0.5, 1.0, and 10 nM PMA and found a similar induction of an adherent monocyte/macrophage morphology after 72-120 h in both cell types.
Markers of RA-induced HL-60 cell differentiation
We also examined the impact of constitutive MZF-1 expression on myelopoiesis, by using flow cytometric analysis to quantitate the expression of a variety of cell surface markers of differentiation. Several markers were identical in both the parental HL-60 and the HL-60-MZF-1 cells before and after induction with RA; these included CD11b which increased with RA induction, CD33 which decreased with RA induction, and CD34, CD13, CD16, and CD14 which remained negative. The leukocyte adhesion molecule, CD18, is expressed on mature granulocytes including HL-60 cells induced with RA. However, after 6 days of exposure to RA, only half as many HL-60-MZF-1 cells expressed CD18 compared to the wild-type HL-60 cells ( Figure 5 ). There was no difference on Northern blot analysis of CD18 expression in the HL-60 and the HL-60-MZF-1 cells ( Figure 6 ) suggsting a post-transcriptional mechanism for the reduced CD18 observed in the HL-60-MZF-1 cells on flow cytometric analysis. These experiments were repeated three times with identical outcomes. The downregulation of c-myc in RA-induced HL-60 cells was similar in the MZF-1-transduced cells and RAR-␣ remained at a steady state level throughout (Figure 6 ), both characteristic of HL-60 cells following RA treatment. 20 
Apoptosis in RA-induced cells
The MZF-1-related induction of cell proliferation may be reflected by an inhibition of programmed cell death normally observed in RA-induced HL-60 cells, so we examined the DNA fragmentation pattern, a distinct biochemical marker for apoptosis, resulting from ethanol, camptothecin, and RA treat- (Figure 7) . Agarose gels stained with ethidium bromide revealed essentially no fragmentation following ethanol (6 days) and extensive fragmentation following the topoisomerase I inhibitor, camptothecin (4 h) as evidenced by the classic DNA 'ladder' in both cells types. However, the transduced HL-60-MZF-1 cells following 6 days of RA displayed distinctly less DNA fragmentation compared to the similarly treated parental HL-60 cells (Figure 7) . To confirm that the delayed RA-induced growth inhibition resulted in part from an inhibition of programmed cell death, we quantitated differences in DNA fragmentation. We used both the TUNEL assay and the diphenylamine assay. TUNEL is an in situ assay that detects the presence of fragmented DNA ends by labeling them with a fluorescein tagged dUTP using terminal transferase. The percent TUNEL positive cells was markedly diminished in the RA-induced HL-60-MZF-1 cells compared to the RA-induced parental HL-60 cells (Figure 8 ). This result was confirmed by measuring solubilized (ie fragmented) DNA in the supernates of induced cells using the diphenylamine assay. 26 The RA-induced HL-60-MZF-1 cells had decreased fragmented DNA compared to the RAinduced parental HL-60 cells afer 4-6 days ( Figure 9 ). However, after 6-8 days there was 'catch-up fragmentation' by the HL-60-MZF-1 cells to a level similar to the parental HL-60 cells ( Figure 9 ). Fragmented DNA could also be detected as hypofluorescent peaks on flow cytometry of propidium iodide stained cells after 6-10 days of treatment with RA using the same technique as shown for cell cycle analysis decribed above. These results suggested that DNA fragmentation or apoptosis was delayed in the MZF-1 transduced cells similar to the delay in RA-induced growth inhibition.
We have previously observed that overexpression of the proto-oncogene bcl-2 in HL-60 cells leads to an inhibition of RA-induced programmed cell death. 26 To determine whether bcl-2 and related cell death genes might be involved with the inhibition of RA-induced apoptosis observed in HL-60-MZF-1 cells, we examined the expression of bcl-2, bcl-x L , and bax in parental HL-60 cells and HL-60-MZF-1 cells following induction with RA. Northern blot analysis revealed no difference between the two cell types in bcl-x L and bax transcript expression (data not shown). However, the bcl-2 transcript appeared to persist (Figure 6 ) in the HL-60-MZF-1 cells following 6 days of RA compared to the wild-type HL-60 cells where the bcl-2 transcript was undetectable following 6 days of RA treatment. To determine whether this difference in RNA expression translated to a difference in expression of the bcl-2 protein, we performed Western blot analysis on cell extracts of HL-60 and HL-60-MZF-1 cells following exposure to RA (Figure 10 ). HL-60 cells express low levels of the bcl-2 protein (26 kDa) which becomes undetectable after 3 days of RA. The HL-60-MZF-1 cells exhibit an elevated level of bcl-2 protein compared to HL-60 cells which persists until after 5 days of RA when it declines to undetectable levels. These results suggest that persistence of bcl-2 expression may in part contribute to the inhibition of apoptosis and delay of RA-induced growth inhibition observed in HL-60-MZF-1 cells.
Discussion
We have used retroviral gene transduction to overexpress MZF-1 in the human myeloid leukemia cell line HL-60 to further characterize the role of the myeloid zinc finger gene, MZF-1, in granulocytic differentiation. The HL-60 cell line has been a useful model for myeloid differentiation as these cells respond to RA with terminal granulocytic differentiation.
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MZF-1 is normally expressed in developing granulocytes, but is downregulated in early myeloid progenitor cells and mature granulocytes. 11 In HL-60 cells, MZF-1 is expressed at a low level and induced upon exposure to RA as the HL-60 cells differentiate into metamyelocytes and myelocytes. 13 Overexpression of MZF-1 in HL-60 cells had no effect on the promyelocytic morphology or baseline growth of the parental HL-60 cells, however after treatment with RA we observed that HL-60-MZF-1 cells continued to proliferate with a delay in the growth inhibition normally exhibited in response to RA. The continued growth of the HL-60-MZF-1 cells compared to the parental HL-60 cells over the first 4-6 days was confirmed with cell cycle analysis which demonstrated a significantly higher percentage of HL-60-MZF-1 cells in S phase after RA treatment compared to the parental HL-60 cells. This effect was also reflected in the morphologic differentiation with a delay in the development of metamyelocytes and myelocytes at 3-4 days. The delay in both the growth inhibition and morphologic differentiation lasted only to days 4-6 with terminal differentiation typical of HL-60 cells proceeding thereafter (Figures 2 and 3 ). These findings suggested to us that perhaps the expression of MZF-1 during myeloid cell development/ expansion (from progenitor cells) might serve to prevent differentiation from proceeding too rapidly thus allowing amplification/expansion of the granulocyte pool to maintain adequate granulocyte numbers in the peripheral blood. This point could be tested in an MZF-1 knock-out experiment where one might expect lower granulocyte counts in the marrow and peripheral blood of mice with a disruption of the MZF-1 gene.
Recent studies have identified the Egr-1 zinc finger transcription factor as a determinant of macrophage differentiation in hematopoietic cells. 30, 31 Overexpression of Egr-1 in HL-60 cells allows induction of macrophage differentiation but not granulocytic differentiation. 31 To test whether MZF-1 might play a similar role by restricting differentiation along the granulocytic lineage, we induced monocytic/macrophage differentiation in HL-60 and HL-60-MZF-1 cells by treating them with PMA. Both cell types responded identically to PMA (0.5-10 nM) with morphologic monocytic differentiation after 72-120 h exposure suggesting that MZF-1 does not possess the same lineage restriction properties that characterize Egr-1.
HL-60 cells induced with RA respond with terminal granulocytic differentiation including apoptosis. 26 We previously observed that the process of programmed cell death and granulocytic differentiation could be separated by inhibiting apoptosis with overexpression of the proto-oncogene bcl-2 in HL-60 cells. 26 HL-60-bcl-2 cells induced with RA results in granulocyte differentiation but little apoptosis thus producing long-lived mature granulocytes. We hypothesized that MZF-1 might perform a similar function to a lesser degree by transiently inhibiting apoptosis to allow the myeloid cell pool to expand before proceeding with terminal granulocytic differentiation. To determine whether MZF-1 was capable of inhibiting the programmed cell death typical of HL-60 cells induced with RA, we assayed for DNA fragmentation, the hallmark of apoptosis, using three different techniques. Both the TUNEL assay for individual cell DNA fragmentation and the diphenylamine assay for DNA fragmentation in a cell population revealed a marked inhibition of apoptosis in the RAinduced HL-60-0MZF-1 cells compared to the parental HL-60 cells. As with the cell proliferation and inhibition of morphologic differentiation, this inhibition of apoptosis was temporary with the total amount of fragmented DNA by day 6 at a similar level to the parental HL-60 cells induced with RA. Examination of the expression of cell death genes in HL-60-MZF-1 cells (bcl-1, bax and bcl-x L ) revealed an increase in both the bcl-2 transcript and protein over wild-type HL-60 cells and this increase persisted following RA induction suggesting that bcl-2 may contribute in part to the inhibition of programmed cell death in these cells. MZF-1 may directly or indirectly regulate expression of bcl-2 which could be addressed in experiments with bcl-2 reporter gene constructs and MZF-1. However, bcl-2 can not be the whole story since there is also a delay in morphologic differentiation which was not observed in HL-60-bcl-2 cells. 26 This observation suggests that MZF may be involved with multiple genes to effect this result. Indeed, others have observed similar effects when MZF-1 is overexpressed in embryonic stem cells; it interferes with the ability of commitment to the hematopoietic lineage. 32 We have previously observed that MZF-1 is able to inhibit apoptosis in murine myeloid IL-3 dependent FDCP.1 cells. 16 This alteration in apoptosis may also contribute to the increased oncogenesis observed in FDCP.1 and NIH 3T3 cells with dysregulated expression of MZF-1. 16, 17 Thus constitutive expression of MZF-1 in RA-induced HL-60 myeloid leukemia induces cell proliferation and delays the RA-mediated growth inhibition and delays myeloid differentiation as well as programmed cell death. The restricted expression of MZF-1 during myelopoiesis may serve as a control, in part, of cell differentiation and apoptosis to allow appropriate expansion of the granulocyte pool and preventing premature differentiation and apoptosis.
Examination of other markers of differentiation using flow cytometry showed little or no difference between the parental HL-60 and HL-60-MZF-1 cells, except for the leukocyte adhesion protein, CD18, which although induced with RA on Northern blot analysis had a two-fold lower level of expression by flow cytometric analysis compared to the RAinduced parental HL-60 cells (Figures 5 and 6 ). MZF-1 may influence post-transcriptional mechanisms to keep CD18 expression low in the face of an upregulated transcript. Interestingly, the expression of CD34 remained low in HL-60-MZF-1 and parental HL-60 cells in both the RA-induced and uninduced state. Previous studies have shown that MZF-1 has tissue specific control of CD34 expression with upregulation in primitive hematopoietic cells and downregulation in nonhematopoietic cells. 15, 32 Two possible reasons for this observed lack of change in CD34 in the HL-60-MZF-1 cells are that the CD34 gene may be methylated and unavailable for transregulation by MZF-1 or that MZF-1 may be necessary but not sufficient for CD34 activation. Future experiments using knock-out technology will help to further define the role of MZF-1 in hematopoiesis as well as other cell systems.
